Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LGVNNASDAQ:PYXSNASDAQ:SNTINASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLGVNLongeveron$1.21-0.8%$1.40$1.14▼$6.40$18.06M0.221.42 million shs64,179 shsPYXSPyxis Oncology$1.14-4.2%$1.15$0.83▼$5.39$70.62M1.18742,626 shs485,185 shsSNTISenti Biosciences$2.28-18.0%$3.33$1.52▼$16.94$59.47M2.23825,452 shs3.88 million shsSTROSutro Biopharma$0.79+0.5%$0.85$0.52▼$5.17$67.04M1.71.11 million shs719,436 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLGVNLongeveron-0.82%-11.03%-13.57%-31.25%-45.50%PYXSPyxis Oncology-4.20%-10.94%-7.32%+1.79%-66.67%SNTISenti Biosciences-17.99%-18.86%-29.63%-35.04%-7.58%STROSutro Biopharma+0.47%-3.99%-9.62%-0.28%-73.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLGVNLongeveron3.1669 of 5 stars3.65.00.00.00.61.71.3PYXSPyxis Oncology2.0684 of 5 stars3.42.00.00.02.50.80.6SNTISenti Biosciences2.4274 of 5 stars3.53.00.00.02.00.01.3STROSutro Biopharma4.0376 of 5 stars3.14.00.04.72.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLGVNLongeveron 3.25Buy$8.67616.25% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00689.47% UpsideSNTISenti Biosciences 3.00Buy$8.50272.81% UpsideSTROSutro Biopharma 2.25Hold$6.11670.26% UpsideCurrent Analyst Ratings BreakdownLatest LGVN, PYXS, SNTI, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.006/12/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/6/2025SNTISenti BiosciencesLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/2/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025PYXSPyxis OncologyRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLGVNLongeveron$2.39M7.56N/AN/A$1.47 per share0.82PYXSPyxis Oncology$16.15M4.37N/AN/A$2.03 per share0.56SNTISenti Biosciences$2.56M23.23N/AN/A$5.31 per share0.43STROSutro Biopharma$62.04M1.08N/AN/A$0.54 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLGVNLongeveron-$15.97M-$6.280.00N/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.590.00N/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)SNTISenti Biosciences-$52.79M-$10.840.00N/AN/AN/A-177.24%-67.38%8/12/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)Latest LGVN, PYXS, SNTI, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/6/2025Q1 2025SNTISenti Biosciences-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 million3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLGVNLongeveronN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLGVNLongeveronN/A5.615.61PYXSPyxis OncologyN/A7.757.75SNTISenti BiosciencesN/A4.224.22STROSutro BiopharmaN/A2.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLGVNLongeveron10.01%PYXSPyxis Oncology39.09%SNTISenti Biosciences25.73%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipLGVNLongeveron11.20%PYXSPyxis Oncology10.60%SNTISenti Biosciences3.12%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLGVNLongeveron2014.93 million13.26 millionNot OptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableSNTISenti Biosciences426.08 million25.27 millionNot OptionableSTROSutro Biopharma24084.46 million81.42 millionOptionableLGVN, PYXS, SNTI, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.11 Consensus Target Price from AnalystsJune 19 at 1:47 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Piper SandlerJune 17 at 2:41 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight RatingJune 16 at 8:17 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by AnalystsJune 16 at 1:35 AM | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16 at 1:03 AM | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLCJune 7, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateJune 3, 2025 | marketbeat.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)May 22, 2025 | marketbeat.com2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LPMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 19, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCostco Stock at $1K: Dominance or Danger Zone?By Jeffrey Neal Johnson | May 23, 2025View Costco Stock at $1K: Dominance or Danger Zone?3 Reasons Salesforce Could Be Back at All-Time Highs by JuneBy Sam Quirke | May 21, 2025View 3 Reasons Salesforce Could Be Back at All-Time Highs by JuneIntuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?By Jeffrey Neal Johnson | June 4, 2025View Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?Why Amazon Could Be About To Breakout To $250By Sam Quirke | June 19, 2025View Why Amazon Could Be About To Breakout To $250Jabil Stock Hits Highs on AI Tailwinds and Strong BuybacksBy Thomas Hughes | June 18, 2025View Jabil Stock Hits Highs on AI Tailwinds and Strong BuybacksLGVN, PYXS, SNTI, and STRO Company DescriptionsLongeveron NASDAQ:LGVN$1.21 -0.01 (-0.82%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.27 +0.06 (+4.96%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Pyxis Oncology NASDAQ:PYXS$1.14 -0.05 (-4.20%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.44%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Senti Biosciences NASDAQ:SNTI$2.28 -0.50 (-17.99%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.20 -0.08 (-3.51%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Sutro Biopharma NASDAQ:STRO$0.79 +0.00 (+0.47%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.84 +0.04 (+5.57%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
